Focus Partners Advisor Solutions LLC Buys 2,662 Shares of Zoetis Inc. $ZTS

Focus Partners Advisor Solutions LLC raised its stake in Zoetis Inc. (NYSE:ZTS) by 58.1% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 7,243 shares of the company’s stock after purchasing an additional 2,662 shares during the period. Focus Partners Advisor Solutions LLC’s holdings in Zoetis were worth $1,130,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ZTS. Brighton Jones LLC increased its position in shares of Zoetis by 180.4% during the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock worth $754,000 after acquiring an additional 2,978 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Zoetis by 4.2% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 68,508 shares of the company’s stock worth $11,183,000 after acquiring an additional 2,748 shares in the last quarter. KBC Group NV increased its position in shares of Zoetis by 14.1% during the first quarter. KBC Group NV now owns 315,823 shares of the company’s stock worth $52,000,000 after acquiring an additional 39,007 shares in the last quarter. Hills Bank & Trust Co increased its position in shares of Zoetis by 10.8% during the first quarter. Hills Bank & Trust Co now owns 2,585 shares of the company’s stock worth $426,000 after acquiring an additional 253 shares in the last quarter. Finally, Avidian Wealth Enterprises LLC increased its position in shares of Zoetis by 6.8% during the first quarter. Avidian Wealth Enterprises LLC now owns 3,805 shares of the company’s stock worth $627,000 after acquiring an additional 241 shares in the last quarter. 92.80% of the stock is owned by institutional investors.

Zoetis Stock Performance

NYSE ZTS opened at $147.57 on Tuesday. The company’s 50 day moving average is $148.08 and its 200-day moving average is $153.52. Zoetis Inc. has a 12-month low of $139.34 and a 12-month high of $184.40. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. The firm has a market cap of $65.40 billion, a P/E ratio of 25.40, a price-to-earnings-growth ratio of 2.35 and a beta of 0.90.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The company had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.41 billion. During the same quarter in the previous year, the firm posted $1.56 earnings per share. The company’s quarterly revenue was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Sell-side analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be given a $0.50 dividend. The ex-dividend date of this dividend is Friday, October 31st. This represents a $2.00 annualized dividend and a dividend yield of 1.4%. Zoetis’s payout ratio is 34.42%.

Wall Street Analyst Weigh In

ZTS has been the topic of several analyst reports. Leerink Partners cut shares of Zoetis from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $180.00 to $155.00 in a report on Thursday, July 17th. Leerink Partnrs cut shares of Zoetis from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 17th. Argus restated a “buy” rating and set a $190.00 price target on shares of Zoetis in a report on Tuesday, September 9th. Weiss Ratings restated a “hold (c-)” rating on shares of Zoetis in a report on Wednesday, October 8th. Finally, Piper Sandler boosted their price target on shares of Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. Four research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $195.00.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.